Navigation Links
Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
Date:1/9/2012

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Ambit Biosciences Corporation today announced that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 10 a.m. PST on Thursday, January 12, at The Westin St. Francis in San Francisco. Michael A. Martino, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor.

Ambit's preclinical portfolio includes, CEP-32496, a BRAF inhibitor licensed to Cephalon, and a proprietary CSF1R inhibitor program. For more information, visit www.ambitbio.com.

Contacts:
Ambit Biosciences:
Alan Fuhrman
Chief Financial Officer
(858) 334-2133

Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com

Cindy McGee (Investors)
Russo Partners
(619) 308-6538
cindy.mcgee@russopartnersllc.com

 


'/>"/>
SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
3. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. Ambit Biosciences Strengthens Board of Directors and Executive Team
6. Ambit Biosciences Initiates Two Phase I Clinical Trials
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
(Date:9/9/2017)... , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 ... D.C. offering free MRI brain scans to the public.Where:  ... be parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... Peter ... the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to Texas as a part of its national Swirl: A Wine Tasting Event ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American College of ... its recently formed Corporate Roundtable, a group of individuals and organizations whose collective ... , Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American Board of Multiple ... for the discomforts and hidden dangers of foot fungus, particularly in the warm ... risk for developing fungal infections on the feet or toenails, the Board says. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets a new ... Xlibris on July of 2014). This book details the recent advances and techniques in ... benefit people who have lost all of their natural teeth . , In ...
Breaking Medicine News(10 mins):